Revumenib in relapsed or refractory KMT2Ar acute leukemia - Syndax Pharmaceuticals

Revumenib in relapsed or refractory KMT2Ar acute leukemia - Syndax Pharmaceuticals

Revumenib in relapsed or refractory KMT2Ar acute leukemia - Syndax Pharmaceuticals

Revumenib in relapsed or refractory KMT2Ar acute leukemia - Syndax Pharmaceuticals

Revumenib in relapsed or refractory KMT2Ar acute leukemia - Syndax Pharmaceuticals

Revumenib in relapsed or refractory KMT2Ar acute leukemia - Syndax Pharmaceuticals

Revumenib in relapsed or refractory KMT2Ar acute leukemia - Syndax Pharmaceuticals

Revumenib in relapsed or refractory KMT2Ar acute leukemia - Syndax Pharmaceuticals

Michael Metzger